Protalix BioTherapeutics Announces Research Project For Inflammatory Bowel Disease (IBD)

Protalix BioTherapeutics Announces Research Project For Inflammatory Bowel Disease (IBD)
Protalix Bio Therapeutics recently announced an update on the development of a new oral anti-TNF (PRX-106) for Inflammatory Bowel Disease (IBD). Protalix is a bio-pharmaceutical company highly focused on and committed to developing and commercializing recombinant proteins with therapeutic potential through its own system of plant cell-based expression, the ProCellEx. The company's technique is an exquisite way of developing recombinant proteins at affordable costs on potentially large industrial scales. The first product that resulted from this system was taliglucerase alfa, which has already been approved by the United States Food and Drug Administration (FDA), Israel's Ministry of Health, Brazilian National Health Surveillance Agency (ANVISA), Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS), Australian Therapeutic Goods Administration (TGA) and other national health authorities. According to a recent press release, Protalix's development pipeline currently includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; PRX-106, an orally-delivered treatment for the treatment of Inflammatory Bowel Disease; PRX-110 for the treatment of Cystic Fibrosis; and others. Protalix is developing PRX-106 to treat IBD, an immune reaction to the host’s intestinal microflora that result in imbalance between the beneficial and commensal microflora within the human gut,  ultimately leading to a serious inflammatory response; it can be triggered by genetics, environmental or physiologic fa
Subscribe or to access all post and page content.